Clinical and Economic Impact of Common Multidrug-Resistant Gram-Negative Bacilli | Zendy

Christian G. Giske | Zendy; Dominique L Monnet | Zendy; Otto Cars | Zendy; Yehuda Carmeli | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Clinical and Economic Impact of Common Multidrug-Resistant Gram-Negative Bacilli

Author(s) -

Christian G. Giske,

Dominique L Monnet,

Otto Cars,

Yehuda Carmeli

Publication year - 2007

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.01169-07

Subject(s) - multiple drug resistance , gram , bacilli , microbiology and biotechnology , gram negative bacteria , gram negative bacterial infections , biology , antibiotics , medicine , bacteria , escherichia coli , genetics , gene

During the last decade, the efforts to combat multidrug-resistant (MDR) microorganisms mainly focused on gram-positive bacteria, namely, methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci. While a large number of hospitals have implemented more rigorous infection

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research